I had the pleasure of interviewing Dr. Travis Stiles CEO of Novoron Bioscience, Inc. Novoron is a private biotech company developing novel therapeutic approaches in the treatment of multiple sclerosis, spinal cord injury, and glaucoma. They have developed a remyelination therapy for multiple sclerosis.   

“The Founding principal of Novoron is rigorous development to avoid false negatives at all cost. Translation: develop drugs so they work to the highest possible level.” said Dr. Stiles.

In 2006, one of Dr. Stiles close friends passed away from amyotrophic lateral sclerosis(ALS).
Losing someone so young to this devastating disease was a humbling experience, yet, one that ignited his passion and ultimately changed the direction of his career.

Driven to overcome his own sense of powerlessness, Dr. Stiles began his work in medical research. During his graduate studies, he discovered a receptor in the central nervous system that seemed to be involved with the regeneration of failed nerves.

In 2013, after completing his PhD, Dr. Stiles established a biotech company to develop drugs that could exploit this receptor and potentially repair damaged tissue in the brain and spinal cord. Novoron is developing therapies that can promote regeneration of neuronal tissue in a number of conditions.

In cases of trauma, like in spinal cord injury (SCI), their technology allows nerves to regenerate under conditions that would otherwise be blocked.

In multiple sclerosis (MS), another main focus of Novoron work, current therapies only target the immune system attacks on the brain. Their technology has shown potential to repair MS damage after it occurs, which is a major unmet need in this disease.

While MS and SCI are two major focuses of Novoron’s technology has the potential to help people with many diseases such as ALS, Alzheimer’s, stroke, glaucoma, and more.

To date, their research has been funded almost entirely by invaluable government grants. Unfortunately, recent government cuts has significantly reduced grant opportunities, leading to disruptions in Novoron’s work.

Novoron has been forced to start a YouCaring campaign to help raise the capital necessary to maintain basic research operations through the beginning of their next wave of funding. To do so, they are hoping to raise $16,000 to ensure that both their lab and core personnel are intact heading into the spring.

All contributions made will go directly towards ensuring that no momentum is lost on developing treatments that may very well reverse paralysis and neuronal dysfunction caused by trauma and/or disease.

Novoron’s long-term goal is to ensure the technology they’ve developed is given the best chance to succeed and change the lives of patients with intractable diseases.

We never ask for contributions from MS patients who have high medical costs themselves, but please feel free to share outside of the MS community to keep this vital research going!


Don’t miss part two of my interview with Dr. Travis Stiles where we discuss MS treatments, remyelination, and research funding. This Sunday at 3:00pm EST msandme.airtime.pro

If you missed part one of our interview, it is available on our Youtube channel.